Sarepta Therapeutics, Inc. - Common Stock (SRPT)

FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.

Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys.

H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.

Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,. Elevidys, after a patient succumbed to acute liver failure. 

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.

The company is working with an independent group to determine if there's a better immunosuppressive regimen.